Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals

Hepatology International, Journal Year: 2024, Volume and Issue: 18(5), P. 1396 - 1415

Published: Aug. 8, 2024

Language: Английский

---

Liver-Kidney-Metabolic Health, Sex, and Menopause Impact Total Scores and Monovessel vs. Multivessel Coronary Artery Calcification

Advances in Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 14, 2025

Language: Английский

---

Perspective article: determinants and assessment of cardiovascular risk in steatotic liver disease owing to metabolic dysfunction-addressing the challenge

Metabolism and Target Organ Damage, Journal Year: 2024, Volume and Issue: 4(3)

Published: June 26, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) stands as an independent risk factor for cardiovascular (CVD), which is the leading cause of mortality among MASLD patients. The diverse spectrum cardio-nephro-metabolic and vascular manifestations inherent in highlights complex profile CVD associated with this condition. However, current approaches to assessing lack specificity, predominantly relying on traditional markers. Although it widely accepted that patients advanced fibrosis are more prone risk, recent evidence suggests isolated focus may overlook remarkable phenotypic variability across entire population. Emerging data indicate a progressive escalation parallel severity MASLD, highlighting need precise staging inform accurate assessment. To address challenge, we propose novel sequential approach assessment MASLD. While factors remain essential, incorporating liver-specific parameters enhances stratification guides targeted interventions mitigate substantial burden vulnerable This involves initial screening using FIB-4 NAFLD score, followed by imaging-based non-invasive techniques individuals at intermediate-high fat quantification low-risk individuals. Future prospective investigations should simultaneous use biomarkers imaging modalities evaluate, sex-specific manner, efficacy proposed determine optimal thresholds steatosis

Language: Английский

---

From NAFLD to MASLD: what does it mean?

Expert Review of Gastroenterology & Hepatology, Journal Year: 2024, Volume and Issue: 18(6), P. 217 - 221

Published: June 2, 2024

Language: Английский

---

Lean Metabolic Dysfunction-Associated Steatotic Liver Disease

Journal of Clinical Gastroenterology, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 24, 2025

Goals: To compare outcomes of MASLD in obese and nonobese populations. Background: is emerging as one the leading causes liver failure liver-related morbidity mortality, with an increasing prevalence or lean population. The purpose this study to hepatic oncological between patients BMI nonlean BMI. Study: National Inpatient Sample (NIS) was queried from 2016 2020 for adult hospitalizations MASLD. Exclusion criteria included concurrent diagnoses viral hepatitis, alcoholic primary biliary cholangitis, hereditary hemochromatosis, autoimmune Wilson disease. Outcomes its complications were compared subgroups. Results: Patients had higher mortality rates (odds ratio: 2.10, P <0.001). cohort also odds cirrhosis, portal hypertension, SBP, ascites. subgroup gastrointestinal malignancies including esophageal cancer, gastric pancreatic colorectal cancer. Conclusions: Hospitalized ​​hepatic morbidities, malignancies. These results challenge use a predictor patients. Future studies should focus on therapeutic options their efficacies

Language: Английский

---

Metabolic dysfunction associated steatotic liver disease in lean patients. Diagnostic and treatment challenges

Experimental and Clinical Gastroenterology, Journal Year: 2025, Volume and Issue: 9, P. 96 - 109

Published: March 6, 2025

Relevance. Metabolic-associated steatotic liver disease (MASLD) became the first pathology among all diseases with a tendency for further increase in incidence. Patients MASLD and normal weight are special cohort that is difficult to diagnose treat. The purpose: analyze literature about pathogenesis, prognosis of management lean patients MASLD. Materials methods. search devoted NAFLD or was conducted PubMed Google Scholar databases, these articles included adult body mass index less than 25 kg/m2 general population 23 Asian population. Discussion. observed mainly individuals obesity and/or type 2 diabetes mellitus, but 7%-20% have weight. This specific phenotype complex pathogenesis including visceral obesity, sarcopenia, genetic polymorphism, altered microbiota profile behavioral factors. Lean high prevalence metabolic disorders (arterial hypertension, dyslipidemia, mellitus) increased mortality from cardiovascular diseases, causes, compared healthy people. They can develop same spectrum damage (steatohepatitis, fibrosis, cirrhosis) as obesity. article describes diagnostic approaches people, requiring exclusion alternative causes steatosis, well risk groups identification. treatment challenges lack effective pharmacological therapy, necessity factors lifestyle modification. Conclusion. obtained data do not allow us consider benign disease. In this cohort, it necessary stage screen cardiometabolic early.

Language: Английский

---

Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease

Annals of Pharmacotherapy, Journal Year: 2025, Volume and Issue: unknown

Published: March 12, 2025

Objective: To summarize the current knowledge on therapeutic potential of GLP-1 receptor agonists in managing metabolic associated steatotic liver disease (MASLD). Data Sources: A literature review was conducted using search terms , MASLD NAFLD nonalcoholic fatty treatment and therapy PubMed (from January 1, 2019, through February 2025), National Institutes Health (NIH) Scopus World Organization (WHO) data. Study Selection Extraction: All relevant clinical trials, articles, package inserts, guidelines evaluating clinically evidence regarding were considered for inclusion. Synthesis: RAs have shown promising results treatment. Semaglutide has demonstrated efficacy reducing fat content, inflammation, fibrosis, with trials indicating improvements hepatic biomarkers cardiometabolic risk factors. Similarly, tirzepatide been substantial weight loss significant reductions fibrosis markers. Both agents exert their effects mechanisms involving improved insulin sensitivity, reduced lipid accumulation, attenuation inflammation. Relevance to Patient Care Clinical Practice: Given high prevalence patients obesity type 2 diabetes, semaglutide could play a critical role practice by addressing multiple facets disease. fat, improving biomarkers, mitigating risks, which are leading causes morbidity mortality patients. Incorporating these therapies into significantly enhance patient outcomes targeting both liver-related systemic complications Conclusions: GLP1 show great promoting loss, glycemic control,

Language: Английский

---

Association between metabolic dysfunction-associated steatotic liver disease, metabolic dysfunction subtypes and risk of colorectal cancer: A Prospective Cohort Study

Clinics and Research in Hepatology and Gastroenterology, Journal Year: 2025, Volume and Issue: unknown, P. 102573 - 102573

Published: March 1, 2025

Language: Английский

---

Lean MASLD and Cardiovascular Disease: A Review

Cardiology in Review, Journal Year: 2025, Volume and Issue: unknown

Published: March 21, 2025

Metabolic-associated steatotic liver disease (MASLD), formerly known as nonalcoholic fatty disease, is prevalent worldwide and highly associated with cardiovascular (CVD). Lean MASLD defined by hepatic steatosis cardiometabolic risk factors in individuals a body mass index below 25 Western populations or 23 Asian populations. Paradoxically, some studies indicate that lean an elevated of (CV) CV mortality compared nonlean MASLD. patients exhibit distinctive metabolic, genetic, microbiome profiles contributing to increased visceral adiposity, sarcopenia, fibrosis, systemic inflammation, endothelial dysfunction. This review examines the epidemiology, pathophysiology, outcomes MASLD, addressing discrepancies literature. Furthermore, it highlights current clinical guidelines, emphasizes lifestyle modifications, discusses emerging pharmacotherapies potential treatment options.

Language: Английский

---

Bridging the gap in obesity research: A consensus statement from the European Society for Clinical Investigation

European Journal of Clinical Investigation, Journal Year: 2025, Volume and Issue: unknown

Published: May 15, 2025

Abstract Background Most forms of obesity are associated with chronic diseases that remain a global public health challenge. Aims Despite significant advancements in understanding its pathophysiology, effective management is hindered by the persistence knowledge gaps epidemiology, phenotypic heterogeneity and policy implementation. Materials Methods This consensus statement European Society for Clinical Investigation identifies eight critical areas requiring urgent attention. Key include insufficient long‐term data on trends, inadequacy body mass index (BMI) as sole diagnostic measure, recognition diversity obesity‐related cardiometabolic risks. Moreover, socio‐economic drivers transition across phenotypes poorly understood. Results The syndemic nature obesity, exacerbated globalization environmental changes, necessitates holistic approach integrating frameworks community‐level interventions. advocates leveraging emerging technologies, such artificial intelligence, to refine predictive models address variability. It underscores importance collaborative efforts among scientists, policymakers, stakeholders create tailored interventions enduring policies. Discussion highlights need harmonizing anthropometric biochemical markers, fostering inclusive narratives combating stigma obesity. By addressing these gaps, this initiative aims advance research, improve prevention strategies optimize care delivery people living Conclusion effort marks decisive step towards mitigating epidemic profound impact systems. Ultimately, should be considered being largely consequence model not compatible optimal human health.

Language: Английский

---